- Statutory Instrument 2003 No. 1243
The Misuse of Drugs Act 1971 (Modification) Order 2003
© Crown Copyright 2003
Statutory Instruments printed from this website are printed under the superintendence and authority of the Controller of HMSO being the Queen's Printer of Acts of Parliament.
The legislation contained on this web site is subject to Crown Copyright protection. It may be reproduced free of charge provided that it is reproduced accurately and that the source and copyright status of the material is made evident to users.
It should be noted that the right to reproduce the text of Statutory Instruments does not extend to the Queen's Printer imprints which should be removed from any copies of the Statutory Instrument which are issued or made available to the public. This includes reproduction of the Statutory Instrument on the Internet and on intranet sites. The Royal Arms may be reproduced only where they are an integral part of the original document.
The text of this Internet version of the Statutory Instrument which is published by the Queen's Printer of Acts of Parliament has been prepared to reflect the text as it was Made. A print version is also available and is published by The Stationery Office Limited as the The Misuse of Drugs Act 1971 (Modification) Order 2003, ISBN 0110459938. The print version may be purchased by clicking here. Braille copies of this Statutory Instrument can also be purchased at the same price as the print edition by contacting TSO Customer Services on 0870 600 5522 or e-mail: customer.services@tso.co.uk.
Further information about the publication of legislation on this website can be found by referring to the Frequently Asked Questions.
To ensure fast access over slow connections, large documents have been segmented into "chunks". Where you see a "continue" button at the bottom of the page of text, this indicates that there is another chunk of text available.
| Made | 8th May 2003 | ||
| Coming into force | 1st July 2003 |
Whereas a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and has been approved by a resolution of each House of Parliament;
Now, therefore, Her Majesty, in pursuance of section 2(2) of the Misuse of Drugs Act 1971[1], is pleased, by and with the advice of Her Privy Council, to order, and it is hereby ordered, as follows: -
1. This Order shall be cited as the Misuse of Drugs Act 1971 (Modification) Order 2003 and shall come into force on 1st July 2003.
2. - (1) Schedule 2 to the Misuse of Drugs Act 1971[2] (which specifies the drugs which are subject to control under that Act) shall be amended as follows:
(2) In paragraph 1(a) of Part I of that Schedule there shall be inserted -
-
(a) after "Dihydrocodeinone O-carboxymethyloxime", "Dihydroetorphine"; and
(b) after "Racemorphan", "Remifentanil.".
(3) In paragraph 1(a) of Part III of that Schedule, there shall be inserted -
-
(a) after "Haloxazolam", "4-Hydroxy-n-butyric acid"; and
(b) after "N-Ethylamphetamine", "Zolpidem".
(4) In paragraph 1(b) of Part III of that Schedule, there shall be inserted -
-
(a) before "Atamestane", "4-Androstene-3, 17-dione" and "5-Androstene-3, 17-diol"; and
(b) after "Nandrolone", "19-Nor-4-Androstene-3, 17-dione"; and "19-Nor-5-Androstene-3, 17-diol"[a].
A. K. Galloway
Clerk of the Privy Council
(This note is not part of the Order)
This Order adds eight substances to Schedule 2 to the Misuse of Drugs Act 1971 which specifies drugs which are subject to control under the Act. Two of the substances, Dihydroetorphine and Remifentanil, are added as Class A drugs; and the remaining six, 4-Androstene-3, 17-dione; 5-Androstene-3, 17-diol; 4-Hydroxy-n-butyric acid; 19-Nor-4-Androstene-3; 17-dione, 19-Nor-5-Androstene-3, 17-diol[a] and Zolpidem, are added as Class C drugs.
Notes:
[1] 1971 c. 38.back
[2] Schedule 2 has been amended by S.I. 1973/771, 1975/421, 1977/1243, 1979/299, 1983/765, 1984/859, 1985/1995, 1986/2230, 1989/1340, 1990/2589, 1995/1966, 1996/1300, 1998/750 and 2001/3932.back
[a] Amended by Correction Slip. In article 2, paragraph (4) sub-paragraph (b) of the Order, and in the Explanatory Note that accompanies the Order, "19-Nor-5-Androstene-13, 17-diol" should in both cases read "19-Nor-5-Androstene-3, 17-diol" back
ISBN 0 11 045993 8